Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation

Efficacy of ibrutinib in the treatment of CLL patients with del(17p) and TP53 mutation

Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trialsПодробнее

Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials

Treatment recommendations for patients with CLL with del(17p) and TP53 aberrationsПодробнее

Treatment recommendations for patients with CLL with del(17p) and TP53 aberrations

Obinutuzumab, Ibrutinib, & Venetoclax in 17p / TP53 CLL - Dr. Stephan Stilgenbauer ASH 2022Подробнее

Obinutuzumab, Ibrutinib, & Venetoclax in 17p / TP53 CLL - Dr. Stephan Stilgenbauer ASH 2022

Updates in CLL - 2023 Best of Hematology ConferenceПодробнее

Updates in CLL - 2023 Best of Hematology Conference

Ibrutinib’s Efficacy in CLL Patients with Various Gene MutationsПодробнее

Ibrutinib’s Efficacy in CLL Patients with Various Gene Mutations

Anderson MA (2013): Targeting Bcl-2 in the treatment of leukemia and lymphomaПодробнее

Anderson MA (2013): Targeting Bcl-2 in the treatment of leukemia and lymphoma

CLL: Optimal approaches for patients with deletion 17pПодробнее

CLL: Optimal approaches for patients with deletion 17p